Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,242.39
(
-1.03%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 139920

Tuesday, 04/10/2012 12:01:20 PM

Tuesday, April 10, 2012 12:01:20 PM

Post# of 257580
AMGN acquires KAI Pharmaceuticals (private) for $315M in cash:

http://finance.yahoo.com/news/amgen-acquire-privately-held-kai-124500048.html

KAI's lead product candidate, KAI-4169, is a novel agent [in phase-2] being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis… Amgen will acquire worldwide rights, excluding Japan, to KAI-4169.

AMGN evidently likes this program enough to move expeditiously: they are loaning KAI the money to begin phase-3 trials prior to the formal closing of the acquisition.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today